PRFX
Painreform Ltd
NASDAQ: PRFX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.88
-7.84% today
Updated 2026-04-29
Market cap
$1.72M
P/E ratio
—
P/S ratio
101.35x
EPS (TTM)
$-7.47
Dividend yield
—
52W range
$2 – $12
Volume
0.6M
Painreform Ltd (PRFX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+69.8%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+100.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.4%
Last 1 reports
Positive reaction rate
100%
1 of 1 quarters
Largest single-day move
+1.4%
2025-11-27
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-11-27 | $0.00 | — | $0.93 | $0.94 | +1.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 | $0.00 | — | — | — |
| 2025-06-30 | $0.00 | $-1.09 | — | — | — |
| 2025-03-31 | $-7.68 | $-2.32 | +69.8% | — | — |
| 2024-12-31 | $-7.68 | $-2.32 | +69.8% | — | — |
| 2024-09-30 | $-4.74 | $-18.96 | -300.0% | — | — |
| 2024-06-30 | $-6.24 | $-10.68 | -71.2% | — | — |
| 2024-03-31 | $-2.40 | $-2.72 | -13.3% | — | — |
| 2023-12-31 | $-1.49 | $-3.11 | -108.7% | — | — |
| 2023-09-30 | $-1.40 | $0.48 | +134.3% | — | — |
| 2023-06-30 | $-0.25 | $-1.97 | -688.0% | — | — |
| 2023-03-31 | $-0.32 | $-0.22 | +31.3% | — | — |
| 2022-12-31 | $-0.15 | $-0.30 | -100.0% | $86000.00 | — |
Frequently asked questions
Has Painreform Ltd beaten earnings estimates?
Painreform Ltd has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +69.8% over the last 2 quarters.
How does PRFX stock react to earnings?
PRFX stock has moved an average of +1.4% in the trading day following earnings over its last 1 reports, with positive reactions in 100% of those quarters.